Contact Us marketing@medicilon.com
ABOUT
Company Profile
Corporate Culture
Management Team
Company History
Message from the CEO
Honors and Awards
SERVICES
SERVICES
01 Drug Discovery
Chemistry Research Biology Research Early Pharmacokinetics
02 Pharmaceutical Research
Intermediates Active Pharmaceutical Ingredients Pharmaceutical preparation Analytical Method Development and Quality Control CMC Filings Analytical Testing Center
03 Preclinical Research
Pharmacology & Pharmacodynamics Drug Safety Evaluation DMPK Bioanalysis IND Filings
PLATFORM
PLATFORM
01 One-stop Integrated Services
Liposome Drug Development Drug Discovery Pharmaceutical Research Preclinical Research Botanical Drug Preclinical R&D
02 Innovative Drug R&D Services
Peptide Drug Conjugate (PDC) Antibody Nucleic Acid Drug Cellular Immunotherapies mRNA Vaccine PROTAC ADC
03 Key Technical Services for Drug R&D
Cytokine and Biomarker Detection Metabolite Identification (MetID) Drug Forming Research Flow Cytometry Technology SEND Format Conversion Flow Sorting NanoString nCounter Detection Routes of Drug Administration
04 Drug Efficacy Evaluation for Common Diseases
Rodent Cerebrovascular Disease Inflammatory and Immune Diseases IO Pharmacodynamic Model
05 High-end Preparations Technology Platform
Skin Topical Preparation Ophthalmic drug Inhalation drug
06 Targeted Drugs R&D Services
STAT3-targeted Drugs R&D Service KRAS-targeted Drugs R&D Service GLP-1 New Drug R&D Service
07 Safety Assessment Lab of Process Chemistry

08 Public Services
CAREERS
Talent Development
Campus Recruitment
Recruitment
NEWS
Medicilon Events
Featured Stories
Market Events
Videos
A.C.E.
INVESTORS
Stock Information
Investment Contact
CLIENT CENTER
Intellectual Property Protection
Clients Testimonials
Downloads
Partnerships
Medicilon Support
Newsletters
CN
×
中
Close Button
Customer Center
Customer Center
Case Studies Clients Testimonials Downloads Partnerships Intellectual Property Protection Newsletters
HomeClient CenterMedicilon Support
IND 100 Publications
Nov 22,2023
Medicilon Assists Huaota's CD73-targeting ADC approved for clinical use in US
Recently, Shanghai Huaota Biopharmaceutical Co., Ltd. (Huaota) received a notification from the US FDA, agreeing that the third-generation antibody drug conjugate (ADC) project HB0052 developed by the company targeting the CD73 antigen will enter clinical trials. This is the first antibody conjugate drug project approved by Huaota Biotech to enter clinical trials by the FDA.
See More
Medicilon Assists Huaota's CD73-targeting ADC approved for clinical use in US
Nov 13,2023
Medicilon Assists Gluetacs Therapeutics' second molecular rubber pipeline line GT929 achieves dual filing and batching in China and US
​On October 27, Gluetacs Therapeutics' second Class 1 new drug, GT929 capsule, in its molecular glue degrader pipeline, was approved by the U.S. Food and Drug Administration (FDA) to enter clinical trials for the treatment of malignant hematological tumors.
See More
Medicilon Assists Gluetacs Therapeutics' second molecular rubber pipeline line GT929 achieves dual filing and batching in China and US
Nov 01,2023
Medicilon assists LX-132 capsule, a new-targeted anti-tumor drug developed by Salustier Biosciences, successfully obtained clinical approval for a Class I new drug
Recently, LX-132 capsules, a new generation of irreversible kinase inhibitor independently developed by Salustier Biosciences, received a drug clinical trial approval notice from the NMPA. Medicilon has provided a full set of preclinical research services for the research and development of LX-132.
See More
Medicilon assists LX-132 capsule, a new-targeted anti-tumor drug developed by Salustier Biosciences, successfully obtained clinical approval for a Class I new drug
Aug 24,2023
Medicilon Assists ABM Therapeutics to Obtain US FDA Orphan Drug Qualification for ABM-1310 for the Treatment of Patients with Brain Glioblastoma Carrying BRAF V600 Mutation
ABM Therapeutics announced that its self-developed small molecule BRAF inhibitor ABM-1310 has obtained orphan drug qualification from the US FDA for the treatment of BRAF V600 mutant brain glioblastoma (GBM). Medicilon provided drug discovery services in a flexible cooperation mode.
See More
Medicilon Assists ABM Therapeutics to Obtain US FDA Orphan Drug Qualification for ABM-1310 for the Treatment of Patients with Brain Glioblastoma Carrying BRAF V600 Mutation
Aug 21,2023
TAK-931 is a cancer therapeutic with a unique mechanism of action. Antitumor efficacy studies for TAK-931 were carried out at Medicilon
Replication stress (RS) is a cancer hallmark; chemotherapeutic drugs targeting RS are widely used as treatments for various cancers. To develop next-generation RS-inducing anticancer drugs, cell division cycle 7 (CDC7) has attracted attention as a target. Researchers have developed an oral CDC7-selective inhibitor, TAK-931, as a candidate clinical anticancer drug. TAK-931 demonstrated marked, dose-dependent antitumor activity, without severe body weight loss. Antitumor efficacy studies for TAK-931 were carried out in two pancreatic PDX models, PHTX-249Pa and PHTXM-97Pa, at Medicilon.
See More
TAK-931 is a cancer therapeutic with a unique mechanism of action. Antitumor efficacy studies for TAK-931 were carried out at Medicilon
Aug 04,2023
Medicilon Assists Yuyao Biotech's STAT3 dual phosphorylation inhibitor YY201 has been approved for clinical trials
Medicilon, as a partner of Yuyao Biotech, provided YY201 with pharmaceutical research services (including raw materials and preparations), preclinical research services (including drug efficacy, pharmacokinetics, safety evaluation) and IND declaration services, helping YY201 successfully pass IND approval and enter the clinical trial stage.
See More
Medicilon Assists Yuyao Biotech's STAT3 dual phosphorylation inhibitor YY201 has been approved for clinical trials
Jul 27,2023
Medicilon Assisted - The IND application of BIOT-001, the first self-developed new drug of Biotime Biotechnology, was approved by the FDA
The IND application for the BIOT-001 project targeting the S1P1 target declared by Biotime Biotechnology obtained the US FDA's clinical implied license. Medicilon provided preclinical R&D services from target to IND declaration for the R&D of BIOT-001, and made every effort to complete the project with high quality and efficiency.
See More
Medicilon Assisted - The IND application of BIOT-001, the first self-developed new drug of Biotime Biotechnology, was approved by the FDA
Jul 27,2023
Medicilon Assist - The IND application for the first new drug NB002 of Neologics Bioscience was approved by the FDA for clinical application
Recently, Neologics Bioscience announced that its research and development pipeline NB002 for the treatment of solid tumors has successfully passed the review of the US FDA and agreed to conduct phase I clinical trials. Medicilon provided preclinical research services such as safety evaluation and pharmacokinetics.
See More
Medicilon Assist - The IND application for the first new drug NB002 of Neologics Bioscience was approved by the FDA for clinical application
Jul 18,2023
Academic literature published using Medicilon selenoamino acid medium products
​Medicilon provide complete sets of M9 selenomethionine (SeMET) medium for IPTG-induced E.coli expression system, production of selenomethionine-labeled protein and protein crystallography using multi-wavelength anomalous diffraction (MAD).
See More
Academic literature published using Medicilon selenoamino acid medium products
Jul 17,2023
AP39, a novel mitochondria-targeted H2S donor, was designed and synthesized by Medicilon
​Alzheimer's disease (AD) is the most universal age-related neurodegenerative disease. AP39 is a newly synthesized mitochondrially targeted H2S donor on mitochondrial function. AP39 increases intracellular H2S levels, mainly in mitochondrial regions. AP39 exerts dose-dependent effects on mitochondrial activity in APP/PS1 neurons. AP39, a novel mitochondria-targeted H2S donor, was designed and synthesized by Medicilon.
See More
AP39, a novel mitochondria-targeted H2S donor, was designed and synthesized by Medicilon
Stock Code
688202

Global

Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)

Tel: +1(781)535-1428(U.S.)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

  

Address: 5th Floor, 62, Banpodae-ro 4-gil, Seocho-gu, Seoul, 06719 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Facebook icon
Twitter icon
Linkedin icon
Youtube icon
© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy
Website Map
-->